SCHEMBL19366271

SCHEMBL19366271

C1=NC1c1ccc(-c2ccc3c(-n4cnc5ccccc54)cccc3c2)cc1

nearest known ligand 0.37

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 5/20 0.37
HTT P42858 4/20 0.37
HCAR1 Q9BXC0 1/20 0.36
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
PTK2B Q14289 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
POLB P06746 1/20 0.35
ROCK1 Q13464 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17531394 0.87 HTT (0.46) FGFR1HTTHCAR1CYP11B1CYP11B2
SCHEMBL16147541 0.83 FGFR1 (0.52) FGFR1HTTHCAR1ALDH1A1KDM4E
SCHEMBL16148262 0.81 FGFR1 (0.38) FGFR1HTTHCAR1KDM4EMAPT
SCHEMBL16148087 0.81 HTT (0.55) FGFR1HTTALDH1A1KDM4ERAB9A
SCHEMBL16148177 0.80 ALDH1A1 (0.49) FGFR1HTTALDH1A1MAPTKMT2A
SCHEMBL16148408 0.78 NISCH (0.40) FGFR1HTTHCAR1ALDH1A1KDM4E
SCHEMBL16147619 0.77 GAK (0.47) FGFR1HTTALDH1A1KDM4ERAB9A
SCHEMBL16158495 0.77 RAB9A (0.47) FGFR1HTTCYP11B1CYP11B2ALDH1A1
SCHEMBL16147477 0.76 FGFR1 (0.60) FGFR1ALDH1A1KDM4ERAB9ASMN1; SMN2
SCHEMBL30955935 0.76 HCAR1 (0.56) FGFR1HTTHCAR1POLBROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10617685-B2 Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity UNIVERSITY OF MARYLAND, BALTIMORE (US) 2020-04-14 US disclosed
US-20170266181-A1 NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY UNIVERSITY OF MARYLAND, BALTIMORE (US) 2017-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10617685-B2 Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity AR, NR5A1, BRCA1 FGFR1 1290/4885HTT 1667/4885HCAR1 346/4885
US-20170266181-A1 NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY AR, NR5A1, BRCA1 FGFR1 1290/4885HTT 1667/4885HCAR1 346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.